Nearly one in five patients with type 2 diabetes abandons a newly prescribed glucose-lowering medication within three months, according to a demographic study evaluated by the MASTERMIND Consortium and reported by Medscape. Researchers analyzed data from 135,410 individuals prescribed one of five drug classes to determine if socioeconomic factors or medical history could predict treatment discontinuation. The model failed to reliably forecast which patients would stop taking their medications, prompting calls for prescribers to pivot away from generalized assumptions and focus directly on drug-specific side-effect profiles.
Discontinuation Rates and Demographic Trends in 2024
The study revealed that 26,138 patients—amounting to 19.30% of the total cohort—discontinued their newly prescribed therapies within the 3-month window. While income level and smoking status did not alter discontinuation rates across any of the five drug classes, demographic splits emerged in specific categories. Black, mixed, and other minority ethnic groups stopped taking thiazolidinediones (TZDs) at higher rates than other populations. Across all five classes, women discontinued their new prescriptions more frequently than men, with the largest gender disparity appearing among patients prescribed TZDs.
These findings challenge longstanding clinical intuition regarding patient adherence. Patrick Brent Smith, MD, program director of the Mississippi Delta Family Medicine Residency Program and a board member of the American Academy of Family Physicians, noted that practitioner assumptions often drive prescribing choices rather than hard science. Instead of relying on demographic guesswork, Smith stated that treatment decisions must center on drug-specific side-effect risks alongside glycaemic and cardiometabolic benefits.
Second-Line Medication Claims Data From 2023
Broader claims data point to widespread medication churn across the diabetes formulary, involving GLP-1 receptor agonists, statins, and blood pressure medications. A 2023 review of private health plan claims evaluated 82,624 patients with type 2 diabetes over a 3-year period to track utilization of five second-line medications: DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, sulfonylureas, and TZDs. The analysis showed that 38% of patients discontinued some form of medication.
Discontinuation rates for GLP-1 receptor agonists reached 50%, while the remaining four drug classes saw discontinuation rates range between 36.6% and 39.4%. Patients swapped DPP-4 inhibitors more often than any other drug, at a rate of 8.7%, whereas sulfonylureas experienced the lowest switching rate at 3.0%. Younger adults aged 18 to 44 and female patients faced the highest risk for discontinuation. Smith identified cost as the primary driver behind these cessation patterns, pointing to a 2020 claims review showing that only 47.4% of patients prescribed GLP-1 receptor agonists remained adherent by their second year.
Clinical Adjustments and Cardiovascular Considerations
Managing type 2 diabetes requires continuous dialogue and flexible prescribing strategies to accommodate patient tolerances. Smith emphasized that clinicians must adjust therapies dynamically to fit individual needs, such as prescribing smaller doses of gastro-agitating metformin for patients with restricted restroom access during work hours. A separate study published in the American Journal of Managed Care recommends reviewing pharmacy claims to catch early warning signs, including delayed refills, stretched prescription limits, high out-of-pocket expenses, and gastrointestinal side effects.
As comorbidities accumulate, patient care frequently intersects with cardiology. Nishant Shah, MD, associate professor of medicine and cardiology at the Duke Heart Center, outlines a structured evaluation process before issuing a new prescription. Shah first reviews clinical evidence for safety and positive cardiovascular outcomes, then evaluates patient-level factors like past drug tolerance, current medications, and existing comorbidities to prevent adverse interactions. Once alignment is reached through patient discussions regarding benefits, risks, and financial access, Shah advocates for early integration of SGLT2 inhibitors and GLP-1 receptor agonists for newly diagnosed diabetes patients presenting with heart failure or atherosclerotic cardiovascular disease.
Frequently Asked Questions About Diabetes Medication Adherence
Why do patients abandon GLP-1 receptor agonists at higher rates than other diabetes medications?
Claims data from a 2023 review show that half of all patients prescribed GLP-1 receptor agonists discontinued them, largely driven by adverse gastrointestinal side effects and high out-of-pocket expenses.
Do income levels affect whether a patient stops taking diabetes medications?
No, the MASTERMIND Consortium study found that income level did not significantly influence discontinuation rates across any of the five evaluated glucose-lowering medication classes.
Which age groups face the highest risk of discontinuing second-line diabetes therapies?
Claims data indicate that adults aged 18 to 44 carry a higher risk for medication discontinuation compared to older demographics, with female patients also showing elevated cessation rates across drug classes.
Worth a look